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As the Therapeutic Drug Monitoring Subcommittee (TDMS) of the Korean Association 
of Quality Assurance for Clinical Laboratories (KAQACL), we organised two trials as an 
external quality assessment of therapeutic drug monitoring (TDM) and testing for drugs of 
abuse (DOA) in 2014. In each trial, low and high level control materials for TDM testing, and 
positive and negative control materials for DOA testing, were requested from institutions. 
The number of participating laboratories was 107 for the first trial and 106 for the second. 
The average number of drug items provided was 5.7 per institution. The most commonly 
tested substances were, in descending order, valproic acid, digoxin, tacrolimus, phenytoin, 
and vancomycin. The mean inter-laboratory coefficients of variation for low- and high-
level TDM control materials were 8.5% and 7.2%, respectively. The most widely used TDM 
analysers were the Architect i System (Abbott Diagnostics, USA), followed by the Cobas 
Integra (Roche Diagnostics, Switzerland) and the Cobas c501 analyser (Roche Diagnostics). 
The number of participating laboratories for DOA testing was 23% higher that than in 
2013. In 96.9% of cases, our analysis confirmed the suitability of the tests at participating 
DOA laboratories in both trials. In the external quality assessment of TDM by the TDMS of 
KAQACL in 2014, the overall performance of TDM testing was found to be similar to that 
observed in the previous years, and inter-laboratory precision was higher than that in 2013. 
Continuous quality improvement of TDM testing by participation in a proficiency-testing 
program is necessary.
(J Lab Med Qual Assur 2015;37:12-22)
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Table 1. Response rate of the 2014 therapeutic drug monitoring proficiency testing by the Korean Association of Quality 
Assurance for Clinical Laboratories, including data from the previous three years
Test substances
Year
Response rate  (%)
2011 2012 2013 2014
1st 2nd 1st 2nd 1st 2nd 1st 2nd 2014 2011–2013
Acetaminophen 7 7 7 7 7 6 7 7 6.6 6.4
Amikacin 10 10 9 8 8 7 7 8 7.0 8.1
Amitriptyline 0 0 0 0 0 0 0 0 0.0 0.0
Carbamazepine 60 59 58 55 55 54 52 53 49.3 53.2
Cyclosporine 46 47 46 47 47 47 45 46 42.7 43.7
Digoxin 80 80 78 77 76 75 73 73 68.5 72.7
Ethosuximide 0 0 0 0 0 0 0 0 0.0 0.0
Free phenytoin 3 2 2 2 2 2 2 1 1.4 2.0
Free valproic acid 1 1 1 1 2 1 1 1 0.9 1.1
Gentamicin 7 7 7 7 6 5 5 5 4.7 6.1
Lithium 32 31 33 32 33 33 36 34 32.9 30.3
Methotrexate 17 17 17 17 18 18 18 16 16.0 16.2
Phenobarbital 46 46 45 43 43 41 39 37 35.7 41.2
Phenytoin 63 63 62 60 59 59 56 54 51.6 57.1
Primidone 0 0 0 0 0 0 0 0 0.0 0.0
Salicylate 5 5 6 6 5 5 5 5 4.7 5.0
Sirolimus 8 8 9 9 9 9 10 10 9.4 8.1
Tacrolimus 46 46 51 53 53 53 55 56 52.1 47.1
Theophylline 60 59 56 51 52 50 48 46 44.1 51.2
Tobramycin 6 6 5 5 5 4 4 4 3.8 4.8
Valproic acid 92 92 91 92 93 92 92 91 85.9 86.1
Vancomycin 46 47 48 49 52 51 55 54 51.2 45.7
Total no. of institutions 108 108 107 107 106 105 107 106 25.8 26.6
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Table 2. Percentage of tests carried out using a given instru-
ment for therapeutic drug monitoring at participating 
institutions as assessed by the Korean Association of Quality 




2011 2012 2013 2014
Abbott Architect i System 21.1 33.2 37.4 42.1
Roche Cobas Integra 17.6 19.5 19.9 17.5
Roche Cobas c501 (Cobas 6000) 6.9 6.0 6.5 7.2
Roche/Hitachi Systems 5.7 5.8 5.7 4.2
Siemens Diagnostics Advia Centaur 1.8 2.6 3.9 4.2
Siemens Diagnostics Dimension 3.5 4.0 2.7 3.7
Beckman UniCel DxC Synchron 2.4 2.4 2.3 3.4
Siemens Diagnostics Viva-E 5.2 3.2 3.4 2.7
Abbott TDx/TDxFLx 3.3 2.3 2.3 2.0
Abbott AxSym 19.5 8.2 5.5 1.5
Toshiba chemistry analyzer 2.5 2.1 1.8 1.3
AVL Scientific 0.6 0.8 1.0 1.2
Waters LC/MS/MS 1.6 1.1 1.2 1.2
Olympus AU 1.7 1.8 0.9 1.0
Roche Cobas e601/E170 0.9 0.8 0.9 1.0
Nova CRT/Nucleus 0.9 0.8 0.9 0.7
Abbott Architect c system/Aeroset 0.6 0.5 0.7 0.5
Agilent technologies 0 0.5 0.5 0.5
Siemens Diagnostics Vista - 0.4 0.5 0.5
Nova 0.2 0.2 0.2 0.3
Radioimmunoassay 0 0.3 0.3 0.3
Roche 9100 Series (ISE Mode) 0.1 0.5 0.2 0.3
Vitros 5,1 FS Chemistry System 0.9 0.8 0.6 0.3
Varian (AAS) 0.2 0.2 0.2 0.2
Other Methods 0.5 0.3 0.1 2.0
Total 100.0 100.0 100.0 100.0
Values are presented as %.
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Table 8. Drugs of abuse and the number of participating laboratories showing the percentage of tests that were deemed suitable 
following the proficiency testing by the Korean Association of Quality Assurance for Clinical Laboratories during 2014
Test substances
Participating laboratories during 2014
14-01 (urine) 14-02 (urine) 14-03 (urine) 14-04 (urine)
d-Methamphetamine 29 (100) 29 (100) 30 (97) 30 (97)
Morphine, Free 25 (100) 25 (100) 26 (100) 26 (100)
9-COOH-11-nor-Δ9-THC 23 (100) 23 (100) 24 (100) 24 (100)
Benzoylecgonine 21 (100) 21 (100) 22 (100) 22 (100)
d -Amphetamine 19 (100) 19 (95) 19 (100) 19 (100)
Phencyclidine (PCP) 10 (100) 10 (100) 10 (100) 10 (100)
3,4-Methylenedioxymethamphetamine 9 (100) 9 (100) 9 (100) 9 (100)
Oxazepam 6 (100) 6 (100) 6 (100) 6 (100)
Methadone 4 (100) 4 (100) 4 (100) 4 (100)
Nordiazepam 4 (100) 4 (100) 4 (100) 4 (100)
Ethanol 3 (100) 3 (100) 3 (100) 3 (100)
Nortriptyline 3 (100) 3 (100) 3 (100) 3 (100)
Secobarbital 2 (100) 2 (100) 3 (100) 3 (100)
Propoxyphene 2 (100) 2 (100) 2 (100) 2 (100)
Lysergic acid diethylamide (LSD) 1 (100) 1 (100) 1 (100) 1 (100)
Values are presented as no. of laboratories examined (% of laboratories passing).
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약물검사분과 신빙도조사 결과보고(2014)
고대현1 • 정태동1 • 구금경1 • 전사일1 • 김정호2 • 대한임상검사정도관리협회 약물 
검사분과위원회
1울산대학교 의과대학 서울아산병원 진단검사의학과, 2연세대학교 의과대학 세브란스병원 진단검사의학과
대한임상검사정도관리협회 약물검사분과에서는 2014년 총 2회에 걸쳐 치료적약물농도검사 및 남
용약물검사의 신빙도조사사업을 시행하였다. 1회차 및 2회차 모두 두 가지 농도의 치료적약물농도
검사 정도관리물질 그리고 양성 및 음성의 남용약물검사 정도관리물질을 대상기관에 발송하여 평
가하였다. 치료약물농도검사 신빙도조사에 참여한 기관은 1차 107기관, 2차 106기관이었다. 기관
당 약물농도 검사종목 수는 평균 5.7종목이었다. 가장 많은 기관에서 회신한 약물농도 검사종목은 
valproic acid이고 그 다음은 digoxin, tacrolimus, phenytoin, vancomycin 순이었다. 저농도와 고농도 
정도관리물질의 검사실 간 변이계수는 각각 8.5%, 7.2%였다. 검사장비는 Architect i System (Abbott 
Diagnostics, USA)을 가장 많이 사용하였고, Cobas Integra (Roche Diagnostics, Switzerland), Cobas 
c501 (Roche Diagnostics) 순이었다. 남용약물검사 신빙도조사 참여기관은 2013년보다 약 23% 증
가하였고, 정답률은 1, 2회차 모두 96.7%였다. 2014년도 약물검사분과위원회 신빙도조사사업결과 
치료적약물농도검사의 정밀도가 향상되었다. 약물검사를 실시하는 각 검사실에서는 지속적인 신빙
도조사사업 참여를 통해 검사의 질을 높여나가야 할 것으로 생각되었다.
(J Lab Med Qual Assur 2015;37:12-22)
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